Walden: targeting podocytes as linchpin for kidney function
Backed by Arch and UCB, Walden to enter the clinic next year with a mAb and small molecule targeting podocytes for kidney diseases
Launched in October with $51 million in an Arch- and UCB Ventures-led series A, Walden aims to test its theory that targeting podocytes can make diseased kidney tissue healthy again.
Walden Biosciences Inc. President and CEO Blaine McKee and Arch Venture Partners Managing Partner Steve Gillis have a long history. The two met in the late 1990s when Gillis was CEO at Corixa Corp. and McKee was in BD at Genzyme Corp., where he spent 15 years, 1996-2011. ...